Impact of Escitalopram on Nocturnal Sleep, Day-Time Sleepiness and Performance Compared to Amitriptyline: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects

Abstract

Introduction: Antidepressant drugs vary in their effects on sleep, day-time sedation and performance. Up to now, no data are available for either escitalopram (ESCIT) or amitriptyline (AMI), measuring these by an objective test, such as the multiple sleep latency test (MSLT).

Subjects and Methods: We therefore investigated the impact of a single evening dose of 10 mg ESCIT on polysomnographically recorded nocturnal sleep, day-time sleepiness and performance in comparison to 75 mg AMI and placebo (PLAC) in healthy male subjects.

Results: Both antidepressants significantly suppressed REM sleep (p<0.001). Although polysomnographically measured sleep continuity was impaired after ESCIT (p=0.006), subjective estimates of sleep parameters did not differ. Periodic limb movements (PLMS) were increased after AMI (p<0.001) but not after ESCIT. Processing speed and performance were enhanced after ESCIT compared with AMI (p=0.011), but not with PLAC. Next-day alertness was significantly impaired by AMI (p=0.012), but not by ESCIT. Mean day-time sleep onset latencies increased significantly after evening ESCIT (p<0.001). In contrast, AMI led to a pronounced increase of day-time sleepiness (p=0.007).

Discussion: This study demonstrates that single evening doses of either AMI or ESCIT exhibit different effects on next-day vigilance and alertness in terms of a slightly stimulating effect of ESCIT and a significant reduction after AMI.

References

• 1 Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients.  Neuropsychopharmacology. 1995;  12 159-165
• 2 Atlas, scoring rules. Recording and scoring leg movements.  Sleep. 1991;  16 749-759
• 3 Bakshi R. Fluoxetine and restless legs syndrome.  J Neurol Sci. 1996;  142 151-152
• 4 Billiard M, Dauvilliers Y. Idiopathic hypersomnia.  Sleep Med Rev. 2001;  5 349-358
• 5 Brickenkamp R. Test d2 – Aufmerksamkeits-Belastungs-Test. Göttingen, Hogrefe Verlag; 1994
• 6 Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.  J. Clin. Psychiatry. 2002;  63 331-336
• 7 Colonna L, Reines EH, Andersen HF. A randomized,double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive patients with major depressive disorder.  Curr Med Res Opin. 2005;  21 1659-1668
• 8 DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.  Cell Mol Neurobiol. 1999;  19 443-466
• 9 Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine induced sleep disturbance in depressed patients.  Neuropsychopharmacology. 1996;  14 437-442
• 10 Fairweather D, Kerr J, Hilton S. et al . A placebo-controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers.  Br J Pharmacol. 1993;  35 278-283
• 11 Feige B, Voderholzer U, Riemann D. et al . Independent sleep EEG slow-wave and spindle band dynamics associated with 4 weeks of continuous application of short-half-life hypnotics in healthy subjects.  Clin Neurophysiol. 1999;  110 1965-1974
• 12 Fischer-Cornelssen K, Ferner U, Steiner H. [Multifocal psychopharmaceutic testing (“Multihospital trial”.)].  Arzneimittelforschung. 1974;  24 1706-1724
• 13 Gillin JC, Jernajczyk W, Valladares-Neto DC. et al . Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers.  Psychopharmacology (Berl). 1994;  116 433-436
• 14 Görtelmeyer R. Schlaffragebogen SF-A und SF-B; in Collegium Internationale Psychiatriae Scalarum (CIPS). Internationale Skalen für Psychiatrie. Weinheim, Beltz; 1981
• 15 Grimsley S, Jahn M. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors.  Clin Pharmacy. 1992;  11 930-957
• 16 Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system.  Nat Rev Neurosci. 2003;  4 121-130 ; 12: 537–549
• 17 Herberg K. Verkehrs- und Alltagssicherheit bei Medikation mit Citalopram.  Psychopharmakotherapie. 2001;  18 81-88
• 18 Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.  Int Clin Psychopharmacol. 2000;  15 305-318
• 19 Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups.  Science. 1975;  189 (4196) 55-58
• 20 Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states.  Behav Brain Sci. 2000;  23 793-842 ; discussion 904-1121
• 21 Hornyak M, Voderholzer U, Riemann D. Treatment of depression in patients with restless legs syndrome: what is evidence-based?.  Sleep Med. 2006;  7 301-302
• 22 Jones DM, Allen EM, Griffiths AN. et al . Human cognitive function following binedaline (50 mg and 100 mg) and imipramine (75 mg): results with a new battery on tests.  Psychopharmacology. 1986;  89 198-202
• 23 Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.  J Clin Psychiatry. 1997;  58 146-152
• 24 Koppitz EM. The visual aural and digit span test. New York, Grune & Stratton; 1977
• 25 Kryger MH, Roth T, Dement WC. Principles and practice of sleep medicine. 4th edition. Philadelphia, Saunders; 2004
• 26 Lader M, Melhuish A, Frcka G. et al . The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects.  Eur J Clin Pharmacol. 1986;  31 183-190
• 27 Lader M, Andersen HF, Baekdal T. The effect of escitalopram on sleep problems in depressed patients.  Hum Psychopharmacol. 2005;  20 349-354
• 28 Lawlor BA, Newhouse PA, Balkin TJ. et al . A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers.  Biol. Psychiatry. 1991;  29 281-286
• 29 Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2003;  18 211-217
• 30 Monaca C, Boutrel B, Hen R. et al . 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice.  Neuropsychopharmacology. 2003;  28 850-856
• 31 Murck H, Nickel T, Künzel H. et al . State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine.  Neuropsychopharmacology. 2003;  28 348-358
• 32 Nathan PJ, Sitaram G, Stough C. et al . Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor.  Behav Pharmacol. 2000;  11 639-642
• 33 Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality.  Neuropsychobiology. 2000;  42 69-81
• 34 Oswald I, Adam K. Effects of paroxetine on human sleep.  Br J Clin Pharmacol. 1986;  22 97-99
• 35 Ramaekers JG, Muntjewerff ND, O’Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance.  Br J Clin Pharmacol. 1995;  39 397-404
• 36 Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers.  Am J Epidemiol. 1992;  136 873-883
• 37 Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, Government Printing Office; 1968
• 38 Riedel WJ, Eikmans K, Heldens A. et al . Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment.  J Psychopharmacol. 2005;  19 12-20
• 39 Riemann D, Voderholzer U, Cohrs S. et al . Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.  Pharmacopsychiatry. 2002;  35 165-174
• 40 Roeschke J, Kögel P, Schlösser R. et al . Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects.  Psychopharmacology. 1997;  132 44-49
• 41 Rosenberg C, Damsbo N, Fuglum E. et al . Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.  Int Clin Psychopharmacol. 1994;  9 (S 01) 41-48
• 42 Rottach KG, Schaner BM, Kirch MH. et al . Restless legs syndrome as side effect of second generation antidepressants.  J Psychiatr Res. 2008;  43 70-75
• 43 Saletu B. Psychopharmaka, Gehirntätigkeit und Schlaf Neurophysiologische Aspekte der Psychopharmakologie und Pharmakopsychiatrie.  Bibl Psychiatr Basel, Karger. Vol. 155, 1976
• 44 Saletu B, Frey R, Krupka M. et al . Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities.  Sleep. 1991;  14 439-447
• 45 Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers.  J Clin Psychiatry. 1997;  58 348-350
• 46 Sharpley A, Cowen P. Effect of pharmacologic treatments on the sleep of depressed patients.  Biol Psychiatry. 1995;  15 85-98
• 47 Staner L, Kerkhofs M, Detroux D. et al . Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression.  J. Sleep. 1995;  18 470-477
• 48 van Bemmel AL, van den Hoofdakker RH, Beersma DG. et al . Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram.  Psychopharmacology (Berl). 1993;  113 225-230
• 49 Vasar V, Appelberg B, Rimón R. et al . The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers.  Int Clin Psychopharmacol. 1994;  9 203-206
• 50 Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2002;  17 95-102
• 51 Wilson SJ, Bailey JE, Alford C. et al . Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers.  J Psychopharmacol. 2000;  14 378-386
• 52 Wilson SJ, Bailey JE, Rich AS. et al . Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram.  Eur Neuropsychopharmacol. 2004;  14 367-372
• 53 Wingen M, Bothmer J, Langer S. et al . Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.  J Clin Psychiatry. 2005;  66 436-443
• 54 Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep.  Biol. Psychiatry. 2005;  15; 58 (6) 510-514
• 55 Zimmermann P, Fimm B. Testbatterie zur Erfassung von Aufmerksamkeitsstörungen. Version 1.02. Freiburg: Psytest; 1993

Correspondence